CD123 and CD11c populations of dendritic cells, but not CD14 monocytes, are significantly depleted in patients with SzS.

(A) PBMCs from a healthy donor and an SzS patient with high tumor burden were excluded of all lineage-positive cells (cells stained with Lin 1–FITC cocktail, containing antibodies against CD3, CD14, CD16, CD19, CD20, CD56), whereas lineage-negative cells were analyzed for the coexpression HLA-DR and CD11c or CD123. The right upper quadrant numbers represent the percentage of dendritic cells expressing HLA-DR and CD11c or CD123. (B) PBMCs from age-matched healthy donors, mycosis fungoides patients, and SzS patients with different levels of tumor burden were analyzed for the presence of dendritic cells, as described in panel A. Monocytes were defined by the expression of CD14, and only CD14^high cells were analyzed. Data represent means (±SD) of tested patients and are presented as a percentage of all PBMCs gated on forward and side light scatter. *P < .001; **P < .01; ***P < .05 compared with healthy donors. Control antibodies stained 0.1% of PBMCs.